Nanjing Immunophage Biotech Co., Ltd
Shanghai, PuDongXinQu
What changed
Phase II trial registered: IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
2w agoTrial registeredJun 29, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 71 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
946 pre-ticker oncology companies at Phase II
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE1/PHASE2 registered
Jun 16, 2026Advanced Solid Tumor · RECRUITING · sponsor: Nanjing Immunophage Biotech Co., Ltd · IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT07508761 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources